$STAA

5 stories mentioning STAA

Every FINWIRES story that references STAA, newest first.

Top Midday Gainers

Cisco (CSCO) overnight reported a year-over-year jump in fiscal Q3 earnings and revenue, topping market expectations, and raised its fiscal 2026 guidance. It also announced restructuring plans that included lay-offs of nearly 4,000 employees.Shares advanced 12%, with intraday trading volume rising to over 54.4 million from a daily average of about 21.7 million.POET Technologies (POET) and Lumilens unveiled a partnership on Thursday to develop a new class of wafer-level photonic integration for artificial intelligence infrastructure.As part of a supply agreement, Lumilens placed an initial purchase order with POET for Electrical-Optical Interposer-based engines valued at $50 million. Orders may increase to more than $500 million over five years.Shares surged 39% as intraday trading volume soared to over 95.9 million from a daily average of roughly 27.1 million.STAAR Surgical (STAA) reported surprise Q1 earnings late Wednesday as sales more than doubled from a year ago, beating expectations.Shares jumped 11% as intraday trading volume rose to over 2.75 million from a daily average of about 1.27 million.Price: $114.79, Change: $+12.92, Percent Change: +12.68%

$CSCO$POET$STAA

Wire31d ago

Update: STAAR Surgical Shares Rise After Wedbush Upgrade Following Q1 Results

(Updates with recent stock movement and upgrade from Wedbush in headline and first two paragraphs.)STAAR Surgical (STAA) shares rose more than 10% in Thursday afternoon trading after Wedbush Securities upgraded the company's stock following the company's Q1 results that beat market expectations.The investment firm upgraded the stock to outperform from neutral and adjusted the price target to $40 from $26. Trading volume of STAAR stood at more than 2.7 million shares against a daily average of about 1.3 million.The company reported Q1 earnings late Wednesday of $0.10 per diluted share, swinging from a loss of $1.10 a year earlier.Analysts surveyed by FactSet expected a loss of $0.05.Net sales for the three months ended April 3 rose to $93.5 million from $42.6 million a year earlier.Analysts polled by FactSet expected $78.7 million.Price: $32.53, Change: $+3.13, Percent Change: +10.63%

$STAA

Wire32d ago

STAAR Surgical Nearing Inflection Point for Full China Rebound, Wedbush Says

STAAR Surgical (STAA) is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.Analysts said the company reported "strong" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high season during Q2 and Q3, according to the note.Wedbush raised STAAR Surgical's 2026 revenue estimate to $350.1 million from $320.2 million. Analysts polled by FactSet expect $326.1 million.The firm upgraded the stock's rating to outperform from neutral, and raised its price target to $40 from $26.Price: $33.36, Change: $+3.96, Percent Change: +13.48%

$STAA

Research32d ago

Wedbush Upgrades STAAR Surgical to Outperform From Neutral, Adjusts Price Target to $40 From $26

STAAR Surgical (STAA) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$STAA

Sectors66d ago

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, STAAR Surgical (STAA) needs to show that the rebound in China is sustainable after the firm reported much higher preliminary Q1 net sales than consensus, Wedbush said in a note. Wedbush raised the company's price target to $26 from $21, while keeping its neutral rating. STAAR shares jumped 21%.Amazon.com's (AMZN) Amazon Pharmacy said Thursday it is offering Eli Lilly's (LLY) obesity pill Foundayo. Additionally, WW International (WW) said Thursday it is now offering access to Foundayo for weight loss through its Med+ program and affiliated medical groups. Lilly shares rose 0.4%.BridgeBio Pharma (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a note. RBC started coverage of the company with an outperform rating and a price target of $100. BridgeBio shares rose 2.7%.Vanda Pharmaceuticals (VNDA) said Thursday it is calling on the US Food and Drug Administration to withdraw a proposal in the regulator's fiscal 2027 Congressional Budget Justification that would extend drug review timelines. Vanda shares were down 0.3%.

$BBIO$LLY$STAA$VNDA